Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era.

about

Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era.

Item

http://www.wikidata.org/entity/Q42318234

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Impact of CRAB Symptoms in Sur ...... ic Myeloma in Novel Agent Era.

@en

Impact of CRAB Symptoms in Sur ...... ic Myeloma in Novel Agent Era.

@nl

type

Item

label

Impact of CRAB Symptoms in Sur ...... ic Myeloma in Novel Agent Era.

@en

Impact of CRAB Symptoms in Sur ...... ic Myeloma in Novel Agent Era.

@nl

prefLabel

Impact of CRAB Symptoms in Sur ...... ic Myeloma in Novel Agent Era.

@en

Impact of CRAB Symptoms in Sur ...... ic Myeloma in Novel Agent Era.

@nl

P1476

Impact of CRAB Symptoms in Sur ...... ic Myeloma in Novel Agent Era.

@en

P2093

Atsushi Satake

http://www.w3.org/2001/XMLSchema#string

Aya Nakaya

http://www.w3.org/2001/XMLSchema#string

Hideaki Yoshimura

http://www.w3.org/2001/XMLSchema#string

Kazuyoshi Ishii

http://www.w3.org/2001/XMLSchema#string

Masaaki Hotta

http://www.w3.org/2001/XMLSchema#string

Shinya Fujita

http://www.w3.org/2001/XMLSchema#string

Shosaku Nomura

http://www.w3.org/2001/XMLSchema#string

Takahisa Nakanishi

http://www.w3.org/2001/XMLSchema#string

Tomoki Ito

http://www.w3.org/2001/XMLSchema#string

Yoshiko Azuma

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma

P304

6887

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4081/HR.2017.6887

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28286629

http://www.w3.org/2001/XMLSchema#string

P932

5337823

http://www.w3.org/2001/XMLSchema#string